Infliximab does not increase colonic cancer risk associated to murine chronic colitis
Open Access
- 1 January 2016
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (44) , 9727-9733
Abstract
Infliximab does not increase colonic cancer risk associated to murine chronic colitisKeywords
This publication has 30 references indexed in Scilit:
- Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel DiseaseDigestive Diseases, 2016
- Strategies and Resources to Address Colorectal Cancer Screening Rates and Disparities in the United States and GloballyAnnual Review of Public Health, 2013
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammationCytokine, 2012
- A Novel Murine Model of Inflammatory Bowel Disease and Inflammation-Associated Colon Cancer with Ulcerative Colitis-Like FeaturesPLOS ONE, 2012
- Cancer in inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 2012
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Intestinal Inflammation and CancerGastroenterology, 2011
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- The risk of colorectal cancer in ulcerative colitis: a meta-analysisGut, 2001